EUVIMEDEUVIMED entdecken
Open Access

CFHR2 supplementation mitigates pathologies of neuromyelitis optica by regulating complement activation

Wei Jiang, Pengyan He, Mao Lin, Chongyou Zhang, Li Xu, Huiming Xu, Haoyang Li, Fan Zhu, Wenjing Luo, Xuan Li, Guangyou Wang, Shengjun Wang und 4 weitere

Molecular Therapy · 2025

DOI: 10.1016/j.ymthe.2025.08.048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2025. Verfasst von Wei Jiang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Shandong Key Laboratory of Mitochondrial Medicine and Rare Diseases, Research Institute of Neuromuscular and Neurodegenerati…. Hauptthemen laut MEDLINE: Neuromyelitis Optica, Complement Activation, Complement C3b Inactivator Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Guangzhou Municipal Science and Technology Project, Harbin Medical University, Ministry of Education of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing autoimmune disease primarily affecting the optic nerves and spinal cord. While the pathogenesis of NMO involves Aquaporin-4 antibodies (AQP4-IgG) and complement-mediated damage, the specific roles of the complement pathway remain to be fully elucidated. In this study, we found that complement factor H-related protein 2 (CFHR2), a regulator that inhibits the complement C3 alternative pathway, was significantly decreased in the serum of NMO patients and was negatively correlated with the Expanded Disability Status Scale (EDSS) score. Furthermore, we observed a marked reduction in CFHR2 expression in astrocytes in both in vitro and in vivo NMO models. Administration of recombinant human CFHR2 protein or adeno-associated virus (AAV)-mediated overexpression of CFHR2 in astrocytes significantly alleviated NMO-related lesions and motor deficits by inhibiting inflammation in these models. Additionally, CFHR2-modified functionalized exosomes demonstrated efficacy in improving NMO-related lesions and motor dysfunction, offering a promising new therapeutic strategy for NMO.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuromyelitis OpticaComplement ActivationComplement C3b Inactivator ProteinsHumansAnimalsAstrocytesMiceFemaleDisease Models, AnimalMaleDependovirusAdultMiddle AgedAquaporin 4

Stichwörter der Autor:innen

AQP4-IgGCFHR2NF-κBSTAT3demyelinationneuromyelitis optica spectrum disorder

Substanzen

Complement C3b Inactivator ProteinsAquaporin 4

Autor:innen und Institutionen

  • Department of Neurology, Shandong Key Laboratory of Mitochondrial Medicine and Rare Diseases, Research Institute of Neuromuscular and Neurodegenerative Diseases, Qilu Hospital of Shandong University, Jinan, Shandong, Ch…
  • Department of Neurology, Third Affiliated Hospital of Sun Yat-Sen University, 600 Tianhe Road, Guangzhou, Guangdong 510630, China.
  • Precision Medicine Center, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong 523710, China; Medical Research Center, The Fifth Affiliated Hospital of Guangzhou Medical University,…
  • Department of Neurobiology, Harbin Medical University, Harbin 150081, China.
  • Department of Neurology, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
  • Department of Anesthesiology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, China.

Förderung

  • Guangzhou Municipal Science and Technology Project
  • Harbin Medical University
  • Ministry of Education of the People's Republic of China
  • National Natural Science Foundation of China
  • Qilu Hospital of Shandong University
  • Hebei Medical University
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Jiang, W., He, P., Lin, M., Zhang, C., Xu, L., Xu, H., Li, H., Zhu, F., Luo, W., Li, X., Wang, G., Wang, S., Tang, C., Wang, J., Lin, Y., & Yang, S. (2025). CFHR2 supplementation mitigates pathologies of neuromyelitis optica by regulating complement activation. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.08.048

Vancouver

Jiang W, He P, Lin M, Zhang C, Xu L, Xu H, et al. CFHR2 supplementation mitigates pathologies of neuromyelitis optica by regulating complement activation. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.08.048

BibTeX
@article{Jiang2025,
  author = {Jiang, Wei and He, Pengyan and Lin, Mao and Zhang, Chongyou and Xu, Li and Xu, Huiming and Li, Haoyang and Zhu, Fan and Luo, Wenjing and Li, Xuan and Wang, Guangyou and Wang, Shengjun and Tang, Changyong and Wang, Jiani and Lin, Yan and Yang, Shanshan},
  title = {CFHR2 supplementation mitigates pathologies of neuromyelitis optica by regulating complement activation},
  journal = {Molecular Therapy},
  year = {2025},
  doi = {10.1016/j.ymthe.2025.08.048}
}
Kostenlos starten →